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Might positron emission 
tomography actually treat 
micrometastatic cancer?
determine the presence of micrometastatic disease 
are available 4,5, possibly enabling treatments to be 
more specifically targeted.
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We read the interesting pilot study of Dr. Nayot and 
colleagues on the use of preoperative 18F-fluorode-
oxyglucose positron emission tomography (f d g -p e t) 
with computed tomography (c t ) scanning to detect 
metastatic nodes in subjects with endometrial cancer 1. 
Even though the scanning was not sensitive enough 
for this purpose, we hypothesize that f d g  itself might 
actually treat occult micrometastatic disease.
A recent retrospective analysis regarding survival 
in non-small-cell lung cancer (n s c l c ) demonstrated 
improved survival among patients with stages iii and iv 
n s c l c  in a p e t scanning period (1999–2004) as com-
pared with a period before p e t scanning (1994–1998) 2. 
It was concluded that f d g -p e t scanning was, in part, 
independently associated with improved survival 
because of more sensitive detection of tumour spread, 
resulting in stage migration. Interestingly and intrigu-
ingly, the survival advantage was seen in patients who 
experienced f d g -p e t scanning regardless of whether 
they did or did not undergo chemotherapy or standard 
radiation therapy.
Although the radiation dose from f d g -p e t scanning 
is only a fraction of the standard dose to treat solid 
tumours 3, perhaps avid uptake of f d g  by metaboli-
cally active micrometastatic tumour cells results in 
highly localized gamma radiation, leading to tumour 
cell death. Moreover, it is common for lung cancer 
patients, particularly those with stage iii or iv disease 
to have circulating micrometastatic tumour cells 4, 
which might explain the improved survival among 
the patients with stages iii and iv n s c l c  who underwent 
f d g -p e t scanning.
Perhaps f d g  should be investigated as a possible 
treatment modality for micrometastatic tumour burden 
in various cancers. Furthermore, technologies to 